Medical inquiries

Phone: +41 (0)41 767 7255

Mon - Fri 09.00 - 17.00

Email: medinfo.switzerland@bms.com

Websites for your patients

Useful disease information for your patients in a patient-friendly language:

BMS Events

Interested in attending a round table event or learning about BMS' presence at congresses? Check out our events section for information on past and upcoming events in various therapy areas.

 

 

 

Welcome to the BMS portal for health care professionals!

 

This portal is your one-stop-shop for all your needs and questions concerning BMS products in Switzerland! These are some examples of the things you can find:

  • Rich media library with webinars, podcasts, HCP materials, patient brochures and much more
  • Detailed clinical data concerning our approved indications
  • Information on ongoing clinical research in Switzerland
  • Comprehensive calendar with BMS educational events and relevant national and international congresses
  • The relevant BMS team members for your region and interest

 

 

Ready to explore? Please use your existing DocCheck Login to access one of our therapeutic area portals or to access the comprehensive BMS Medicines or News & Events overview

 

 

 

News and recent approvals

 

Icons
Melanoma

OPDUALAG® is now reimbursed for the first-line treatment of adults with metastatic melanoma with PD-L1 < 1% expression.

www.spezialitaetenliste.ch

More information

Icons
Melanoma

November 2023 – Q4W 480 mg dosing with Nivolumab is approved in all melanoma indications.

Q4W dosing is approved for all Nivolumab monotherapy as well as monotherapy maintenance after Nivolumab + Ipilimumab combination treatment in melanoma.

More information

 

 

Icons
Melanoma

October 2023 – Nivolumab as monotherapy is indicated for the adjuvant treatment of adults with completely resected Stage IIB or IIC melanoma.

More information

Icons
Lisocabtagene maraleucel, CD-19 CAR T cell therapy

September 2023 – Swissmedic approved lisocabtagene maraleucel (BREYANZI®) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL) or primary mediastinal large B-cell lymphoma (PMBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

BREYANZI®
▼ This drug is subject to additional monitoring. For further information, please refer to the information for healthcare professionals on swissmedicinfo.ch.

More information

 

 

Icons
Thoracic cancer

July 2023 – Nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumour size ≥ 4 cm or positive lymph node involvement) non-small cell lung cancer (NSCLC) with PD-L1 tumour expression ≥ 1 % in adults

More information

Icons
Melanoma

December 2022 – Nivolumab/Relatlimab for the first-line treatment of adults with unresectable or metastatic melanoma with PD-L1 expression < 1%.

More information

 

 

 

 

 

 

 

02/2024 466-CH-2400001